Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL
Source: Blood - Category: Hematology Authors: Ahn, I. E., Basumallik, N., Tian, X., Soto, S., Wiestner, A. Tags: Lymphoid Neoplasia, Clinical Trials and Observations Letter to Blood Source Type: research
More News: Clinical Trials | Hematology